Aquestive Therapeutics, Inc. Other Noncash Income (Expense)
Aquestive Therapeutics, Inc. (AQST) reported Other Noncash Income (Expense) of -$49.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-11
- Aquestive Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was -$43.00K, a 175.44% decline year-over-year.
- Aquestive Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$6.00K.
- Aquestive Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was -$1.00K.
- Aquestive Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was -$11.00K.
- Aquestive Therapeutics, Inc. other noncash income (expense) for fiscal 2025 was -$1.00K.
- Aquestive Therapeutics, Inc. other noncash income (expense) for fiscal 2024 was -$104.00K, a 150.98% decline from fiscal 2023.
- Aquestive Therapeutics, Inc. other noncash income (expense) for fiscal 2023 was $204.00K, a 292.31% increase from fiscal 2022.
- Aquestive Therapeutics, Inc. other noncash income (expense) for fiscal 2022 was $52.00K, a 82.61% decline from fiscal 2021.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$49.00K 10-Q · filed 2026-08-11 | -$50.00K derived: sum of 3 quarters · filed 2026-08-11 | -$61.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$6.00K 10-Q · filed 2026-05-13 | -$7.00K derived: sum of 2 quarters · filed 2026-05-13 | -$18.00K derived: sum of 3 quarters · filed 2026-05-13 | $39.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$12.00K derived: sum of 2 quarters · filed 2026-03-04 | $45.00K derived: sum of 3 quarters · filed 2026-08-11 | -$1.00K 10-K · filed 2026-03-04 |
| 2025-09-30 | -$11.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $46.00K derived: sum of 2 quarters · filed 2026-08-11 | $0.00 10-Q · filed 2025-11-05 | -$33.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | $57.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $11.00K 10-Q · filed 2026-08-11 | -$22.00K derived: sum of 3 quarters · filed 2026-08-11 | -$74.00K derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$46.00K 10-Q · filed 2026-05-13 | -$79.00K derived: sum of 2 quarters · filed 2026-05-13 | -$131.00K derived: sum of 3 quarters · filed 2026-05-13 | -$118.00K derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | -$33.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | -$85.00K derived: sum of 2 quarters · filed 2026-03-04 | -$72.00K derived: sum of 3 quarters · filed 2026-03-04 | -$104.00K 10-K · filed 2026-03-04 |
| 2024-09-30 | -$52.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | -$39.00K derived: sum of 2 quarters · filed 2025-11-05 | -$71.00K 10-Q · filed 2025-11-05 | -$106.00K derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $13.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | -$19.00K 10-Q · filed 2025-08-11 | -$54.00K derived: sum of 3 quarters · filed 2025-08-11 | -$82.00K derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | -$32.00K 10-Q · filed 2025-05-12 | -$67.00K derived: sum of 2 quarters · filed 2025-05-12 | -$95.00K derived: sum of 3 quarters · filed 2025-05-12 | -$88.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$35.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-05 | -$63.00K derived: sum of 2 quarters · filed 2025-03-05 | -$56.00K derived: sum of 3 quarters · filed 2025-03-05 | $204.00K 10-K · filed 2025-03-05 |
| 2023-09-30 | -$28.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | -$21.00K derived: sum of 2 quarters · filed 2024-11-04 | $239.00K 10-Q · filed 2024-11-04 | $351.00K derived: sum of 4 quarters · filed 2024-11-04 |
| 2023-06-30 | $7.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $267.00K 10-Q · filed 2024-08-06 | $379.00K derived: sum of 3 quarters · filed 2024-08-06 | $158.00K derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $260.00K 10-Q · filed 2024-05-07 | $372.00K derived: sum of 2 quarters · filed 2024-05-07 | $151.00K derived: sum of 3 quarters · filed 2024-05-07 | $212.00K derived: sum of 4 quarters · filed 2024-05-07 |
| 2022-12-31 | $112.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-05 | -$109.00K derived: sum of 2 quarters · filed 2024-03-05 | -$48.00K derived: sum of 3 quarters · filed 2024-03-05 | $52.00K 10-K · filed 2024-03-05 |
| 2022-09-30 | -$221.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | -$160.00K derived: sum of 2 quarters · filed 2023-11-06 | -$60.00K 10-Q · filed 2023-11-06 | -$9.00K derived: sum of 4 quarters · filed 2023-11-06 |
| 2022-06-30 | $61.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $161.00K 10-Q · filed 2023-08-07 | $212.00K derived: sum of 3 quarters · filed 2023-08-07 | $335.00K derived: sum of 4 quarters · filed 2023-08-07 |
| 2022-03-31 | $100.00K 10-Q · filed 2023-05-02 | $151.00K derived: sum of 2 quarters · filed 2023-05-02 | $274.00K derived: sum of 3 quarters · filed 2023-05-02 | $566.00K derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $51.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-31 | $174.00K derived: sum of 2 quarters · filed 2023-03-31 | $466.00K derived: sum of 3 quarters · filed 2023-03-31 | $299.00K 10-K · filed 2023-03-31 |
| 2021-09-30 | $123.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01 | $415.00K derived: sum of 2 quarters · filed 2022-11-01 | $248.00K 10-Q · filed 2022-11-01 | $94.00K derived: sum of 4 quarters · filed 2022-11-01 |
| 2021-06-30 | $292.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $125.00K 10-Q · filed 2022-08-02 | -$29.00K derived: sum of 3 quarters · filed 2022-08-02 | -$202.00K derived: sum of 4 quarters · filed 2022-08-02 |
| 2021-03-31 | -$167.00K 10-Q · filed 2022-05-04 | -$321.00K derived: sum of 2 quarters · filed 2022-05-04 | -$494.00K derived: sum of 3 quarters · filed 2022-05-04 | -$499.00K derived: sum of 4 quarters · filed 2022-05-04 |
| 2020-12-31 | -$154.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-08 | -$327.00K derived: sum of 2 quarters · filed 2022-03-08 | -$332.00K derived: sum of 3 quarters · filed 2022-03-08 | -$188.00K 10-K · filed 2022-03-08 |
| 2020-09-30 | -$173.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | -$178.00K derived: sum of 2 quarters · filed 2021-11-02 | -$34.00K 10-Q · filed 2021-11-02 | -$317.00K derived: sum of 4 quarters · filed 2021-11-02 |
| 2020-06-30 | -$5.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-03 | $139.00K 10-Q · filed 2021-08-03 | -$144.00K derived: sum of 3 quarters · filed 2021-08-03 | $300.00K derived: sum of 4 quarters · filed 2021-08-03 |
| 2020-03-31 | $144.00K 10-Q · filed 2020-05-05 | -$139.00K derived: sum of 2 quarters · filed 2021-03-09 | $305.00K derived: sum of 3 quarters · filed 2021-03-09 | -$260.00K derived: sum of 4 quarters · filed 2021-03-09 |
| 2019-12-31 | -$283.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-09 | $161.00K derived: sum of 2 quarters · filed 2021-03-09 | -$404.00K derived: sum of 3 quarters · filed 2021-03-09 | -$359.00K 10-K · filed 2021-03-09 |
| 2019-09-30 | $444.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | -$121.00K derived: sum of 2 quarters · filed 2020-11-04 | -$76.00K 10-Q · filed 2020-11-04 | |
| 2019-06-30 | -$565.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$520.00K 10-Q · filed 2020-08-04 | ||
| 2019-03-31 | $45.00K 10-Q · filed 2020-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |